Boston Scientific (BSX) Receives a Buy from RBC Capital
In a report released on April 2, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Boston Scientific, with a price target of $115.00. The company’s shares closed last Thursday at $62.82.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Singh Chadha is a 3-star analyst with an average return of 0.8% and a 45.77% success rate. Singh Chadha covers the Healthcare sector, focusing on stocks such as Boston Scientific, Medtronic, and Inspire Medical Systems.
In addition to RBC Capital, Boston Scientific also received a Buy from Jefferies’s Matthew Taylor in a report issued on April 2. However, on April 1, Erste Group assigned a Hold rating to Boston Scientific (NYSE: BSX).
Based on Boston Scientific’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.29 billion and a net profit of $668 million. In comparison, last year the company earned a revenue of $4.56 billion and had a net profit of $566 million
Read More on BSX:
Disclaimer & DisclosureReport an Issue
- Boston Scientific Investors File Lawsuit Over Alleged Misleading Statements About Electrophysiology Business Growth
- AI Models Turn More Positive on Boston Scientific, But Weak Technicals Temper Enthusiasm
- FTC issued Second Request to Penumbra, Boston Scientific over merger review
- Midday Fly By: Sysco buying Restaurant Depot, Uber to acquire Blacklane
- Boston Scientific upside scenario unlikely after data, says Wells Fargo
